Opinions of Company Representatives About Neuromodulation

Sponsor

Moens Maarten (Other)

Overall Status

Completed

CT.gov ID

NCT05013827

Collaborator

(none)

Enrollment

Location

Actual Duration (Days)

169.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.

Condition or Disease	Intervention/Treatment	Phase
Neuromodulation Pain Survey	Behavioral: Filling in an online survey

Study Design

Study Type:

Observational

Actual Enrollment :

39 participants

Observational Model:

Case-Only

Time Perspective:

Cross-Sectional

Official Title:

Opinions of Company Representatives About Neuromodulation for Pain: an Online Survey

Actual Study Start Date :

Sep 2, 2021

Actual Primary Completion Date :

Sep 9, 2021

Actual Study Completion Date :

Sep 9, 2021

Arms and Interventions

Arm	Intervention/Treatment
Company representatives	Behavioral: Filling in an online survey Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.

Arm

Intervention/Treatment

Company representatives

Behavioral: Filling in an online survey

Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.

Outcome Measures

Primary Outcome Measures

Goals of company representatives, evaluated with a self-constructed question. [Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.]
Goals of company representatives to treat patients with neuromodulation for pain.
Company representatives expectations, evaluated with a self-constructed question. [Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.]
Factors that respondents expect to change according to neuromodulation for pain.
Company representatives definition of success of neuromodulation for pain, evaluated with a self-constructed question. [Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.]
Company representatives their definition of success of neuromodulation for pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey.

Exclusion Criteria:

Not a company representative.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Vrije Universiteit Brussel	Jette		Belgium	1090

Sponsors and Collaborators

Moens Maarten

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Moens Maarten, principal investigator, Universitair Ziekenhuis Brussel

ClinicalTrials.gov Identifier:

NCT05013827

Other Study ID Numbers:

OCEAN

First Posted:

Aug 19, 2021

Last Update Posted:

Jan 14, 2022

Last Verified:

Jan 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Jan 14, 2022